PD-L1 TPS I50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients

被引：0
|
作者：
Seo, J. [1 ]
Keam, B. [1 ]
Youk, J. [1 ]
Kim, M. [1 ]
Kim, T. M. [1 ]
Kim, D-W. [1 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1491P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50%
    Takahara, Yutaka
    Abe, Ryudai
    Sumito, Nagae
    Tanaka, Takuya
    Ishige, Yoko
    Shionoya, Ikuyo
    Yamamura, Kouichi
    Nishiki, Kazuaki
    Nojiri, Masafumi
    Kato, Ryo
    Shinomiya, Shohei
    Oikawa, Taku
    THORACIC CANCER, 2023, 14 (27) : 2754 - 2760
  • [2] Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
    Diego de Miguel-Perez
    Alessandro Russo
    Oscar Arrieta
    Murat Ak
    Feliciano Barron
    Muthukumar Gunasekaran
    Priyadarshini Mamindla
    Luis Lara-Mejia
    Christine B. Peterson
    Mehmet E. Er
    Vishal Peddagangireddy
    Francesco Buemi
    Brandon Cooper
    Paolo Manca
    Rena G. Lapidus
    Ru-Ching Hsia
    Andres F. Cardona
    Aung Naing
    Sunjay Kaushal
    Fred R. Hirsch
    Philip C. Mack
    Maria Jose Serrano
    Vincenzo Adamo
    Rivka R. Colen
    Christian Rolfo
    Journal of Experimental & Clinical Cancer Research, 41
  • [3] Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
    de Miguel-Perez, Diego
    Russo, Alessandro
    Arrieta, Oscar
    Ak, Murat
    Barron, Feliciano
    Gunasekaran, Muthukumar
    Mamindla, Priyadarshini
    Lara-Mejia, Luis
    Peterson, Christine B.
    Er, Mehmet E.
    Peddagangireddy, Vishal
    Buemi, Francesco
    Cooper, Brandon
    Manca, Paolo
    Lapidus, Rena G.
    Hsia, Ru-Ching
    Cardona, Andres F.
    Naing, Aung
    Kaushal, Sunjay
    Hirsch, Fred R.
    Mack, Philip C.
    Serrano, Maria Jose
    Adamo, Vincenzo
    Colen, Rivka R.
    Rolfo, Christian
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [4] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    LUNG CANCER, 2016, 99 : 79 - 87
  • [5] Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
    Cabezon-Gutierrez, Luis
    Custodio-Cabello, Sara
    Palka-Kotlowska, Magda
    Alonso-Viteri, Soledad
    Khosravi-Shahi, Parham
    CLINICAL LUNG CANCER, 2021, 22 (05) : 381 - 389
  • [6] DYNAMIC CHANGE OF PD-L1 EXPRESSION ON EXTRACELLULAR VESICLES PREDICTS RESPONSE TO IMMUNE-CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER PATIENTS
    Perez, Diego de Miguel
    Russo, Alessandro
    Gunasekaran, Muthukumar
    Cardona, Andres
    Lapidus, Rena
    Cooper, Brandon
    Kaushal, Sunjay
    Peterson, Christine
    Colen, Rivka
    Naing, Aung
    Adamo, Vincenzo
    Rolfo, Christian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A17 - A18
  • [7] PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
    Feisal, James
    Balakrishna, Pragathi
    Itani, Aleena
    King, Caleb
    Acharya, Pawan
    Vesely, Sara
    Aljumaily, Raid
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [9] Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%
    Takei, Shota
    Kawachi, Hayato
    Yamada, Tadaaki
    Tamiya, Motohiro
    Negi, Yoshiki
    Goto, Yasuhiro
    Nakao, Akira
    Shiotsu, Shinsuke
    Tanimura, Keiko
    Takeda, Takayuki
    Okada, Asuka
    Harada, Taishi
    Date, Koji
    Chihara, Yusuke
    Hasegawa, Isao
    Tamiya, Nobuyo
    Katayama, Yuki
    Nishioka, Naoya
    Morimoto, Kenji
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Kijima, Takashi
    Takayama, Koichi
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [10] Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients
    Ja Yoon Heo
    Shin Hye Yoo
    Koung Jin Suh
    Se Hyun Kim
    Yu Jung Kim
    Chan-Young Ock
    Miso Kim
    Bhumsuk Keam
    Tae Min Kim
    Dong-Wan Kim
    Dae Seog Heo
    Jong Seok Lee
    Scientific Reports, 11
12345